BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

364 related articles for article (PubMed ID: 22655063)

  • 21. Translational Potential of Immune Tolerance Induction by AAV Liver-Directed Factor VIII Gene Therapy for Hemophilia A.
    Samelson-Jones BJ; Arruda VR
    Front Immunol; 2020; 11():618. PubMed ID: 32425925
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Long-term efficacy of adeno-associated virus serotypes 8 and 9 in hemophilia a dogs and mice.
    Sarkar R; Mucci M; Addya S; Tetreault R; Bellinger DA; Nichols TC; Kazazian HH
    Hum Gene Ther; 2006 Apr; 17(4):427-39. PubMed ID: 16610930
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Codon optimization of human factor VIII cDNAs leads to high-level expression.
    Ward NJ; Buckley SM; Waddington SN; Vandendriessche T; Chuah MK; Nathwani AC; McIntosh J; Tuddenham EG; Kinnon C; Thrasher AJ; McVey JH
    Blood; 2011 Jan; 117(3):798-807. PubMed ID: 21041718
    [TBL] [Abstract][Full Text] [Related]  

  • 24. CD4
    Fu RY; Chen AC; Lyle MJ; Chen CY; Liu CL; Miao CH
    Cell Immunol; 2020 Dec; 358():104216. PubMed ID: 32987195
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The Immune Response to the fVIII Gene Therapy in Preclinical Models.
    Patel SR; Lundgren TS; Spencer HT; Doering CB
    Front Immunol; 2020; 11():494. PubMed ID: 32351497
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Phenotypic correction and long-term expression of factor VIII in hemophilic mice by immunotolerization and nonviral gene transfer using the Sleeping Beauty transposon system.
    Ohlfest JR; Frandsen JL; Fritz S; Lobitz PD; Perkinson SG; Clark KJ; Nelsestuen G; Key NS; McIvor RS; Hackett PB; Largaespada DA
    Blood; 2005 Apr; 105(7):2691-8. PubMed ID: 15576475
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Factors influencing therapeutic efficacy and the host immune response to helper-dependent adenoviral gene therapy in hemophilia A mice.
    Brown BD; Shi CX; Rawle FE; Tinlin S; McKinven A; Hough C; Graham FL; Lillicrap D
    J Thromb Haemost; 2004 Jan; 2(1):111-8. PubMed ID: 14717974
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of factor VIII transgenes bioengineered for improved expression in gene therapy of hemophilia A.
    Dooriss KL; Denning G; Gangadharan B; Javazon EH; McCarty DA; Spencer HT; Doering CB
    Hum Gene Ther; 2009 May; 20(5):465-78. PubMed ID: 19222367
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Naked DNA transfer of Factor VIII induced transgene-specific, species-independent immune response in hemophilia A mice.
    Ye P; Thompson AR; Sarkar R; Shen Z; Lillicrap DP; Kaufman RJ; Ochs HD; Rawlings DJ; Miao CH
    Mol Ther; 2004 Jul; 10(1):117-26. PubMed ID: 15233948
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Novel factor VIII variants with a modified furin cleavage site improve the efficacy of gene therapy for hemophilia A.
    Nguyen GN; George LA; Siner JI; Davidson RJ; Zander CB; Zheng XL; Arruda VR; Camire RM; Sabatino DE
    J Thromb Haemost; 2017 Jan; 15(1):110-121. PubMed ID: 27749002
    [TBL] [Abstract][Full Text] [Related]  

  • 31. FVIII expression by its native promoter sustains long-term correction avoiding immune response in hemophilic mice.
    Merlin S; Famà R; Borroni E; Zanolini D; Bruscaggin V; Zucchelli S; Follenzi A
    Blood Adv; 2019 Mar; 3(5):825-838. PubMed ID: 30862611
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Ex vivo gene therapy for hemophilia A that enhances safe delivery and sustained in vivo factor VIII expression from lentivirally engineered endothelial progenitors.
    Matsui H; Shibata M; Brown B; Labelle A; Hegadorn C; Andrews C; Hebbel RP; Galipeau J; Hough C; Lillicrap D
    Stem Cells; 2007 Oct; 25(10):2660-9. PubMed ID: 17615271
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Reprogrammed CD4
    Herzog RW; Kuteyeva V; Saboungi R; Terhorst C; Biswas M
    Front Immunol; 2019; 10():274. PubMed ID: 30842776
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A murine model for induction of long-term immunologic tolerance to factor VIII does not require persistent detectable levels of plasma factor VIII and involves contributions from Foxp3+ T regulatory cells.
    Matsui H; Shibata M; Brown B; Labelle A; Hegadorn C; Andrews C; Chuah M; VandenDriessche T; Miao CH; Hough C; Lillicrap D
    Blood; 2009 Jul; 114(3):677-85. PubMed ID: 19458355
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Lentivirus-mediated platelet gene therapy of murine hemophilia A with pre-existing anti-factor VIII immunity.
    Kuether EL; Schroeder JA; Fahs SA; Cooley BC; Chen Y; Montgomery RR; Wilcox DA; Shi Q
    J Thromb Haemost; 2012 Aug; 10(8):1570-80. PubMed ID: 22632092
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Multiyear therapeutic benefit of AAV serotypes 2, 6, and 8 delivering factor VIII to hemophilia A mice and dogs.
    Jiang H; Lillicrap D; Patarroyo-White S; Liu T; Qian X; Scallan CD; Powell S; Keller T; McMurray M; Labelle A; Nagy D; Vargas JA; Zhou S; Couto LB; Pierce GF
    Blood; 2006 Jul; 108(1):107-15. PubMed ID: 16522813
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Sustained high-level expression of full-length human factor VIII and restoration of clotting activity in hemophilic mice using a minimal adenovirus vector.
    Balagué C; Zhou J; Dai Y; Alemany R; Josephs SF; Andreason G; Hariharan M; Sethi E; Prokopenko E; Jan HY; Lou YC; Hubert-Leslie D; Ruiz L; Zhang WW
    Blood; 2000 Feb; 95(3):820-8. PubMed ID: 10648392
    [TBL] [Abstract][Full Text] [Related]  

  • 38. In vivo expansion of regulatory T cells with IL-2/IL-2 mAb complexes prevents anti-factor VIII immune responses in hemophilia A mice treated with factor VIII plasmid-mediated gene therapy.
    Liu CL; Ye P; Yen BC; Miao CH
    Mol Ther; 2011 Aug; 19(8):1511-20. PubMed ID: 21468007
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Minimal modification in the factor VIII B-domain sequence ameliorates the murine hemophilia A phenotype.
    Siner JI; Iacobelli NP; Sabatino DE; Ivanciu L; Zhou S; Poncz M; Camire RM; Arruda VR
    Blood; 2013 May; 121(21):4396-403. PubMed ID: 23372167
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phenotype correction of hemophilia A mice with adeno-associated virus vectors carrying the B domain-deleted canine factor VIII gene.
    Ishiwata A; Mimuro J; Kashiwakura Y; Niimura M; Takano K; Ohmori T; Madoiwa S; Mizukami H; Okada T; Naka H; Yoshioka A; Ozawa K; Sakata Y
    Thromb Res; 2006; 118(5):627-35. PubMed ID: 16371232
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.